Details of the Drug Combination

General Information of Drug Combination (ID: DC72JHB)

Drug Combination Name
Nizatidine Dichlorphenamide
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Nizatidine   DMGFV3Z Dichlorphenamide   DMH7IDQ
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 25.82
Bliss Independence Score: 25.82
Loewe Additivity Score: 40.25
LHighest Single Agent (HSA) Score: 40.27

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Nizatidine
Disease Entry ICD 11 Status REF
Acid-reflux disorder DA22 Approved [2]
Gastric ulcer DA60 Approved [3]
Peptic esophagitis N.A. Approved [3]
Peptic ulcer DA61 Approved [3]
Nizatidine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Histamine H2 receptor (H2R) TTQHJ1K HRH2_HUMAN Antagonist [5]
------------------------------------------------------------------------------------
Nizatidine Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Nizatidine Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Calcitonin (CALCA) OTZ11LHB CALC_HUMAN Increases Expression [8]
Protachykinin-1 (TAC1) OTM842YW TKN1_HUMAN Increases Expression [8]
------------------------------------------------------------------------------------
Indication(s) of Dichlorphenamide
Disease Entry ICD 11 Status REF
Chronic glaucoma 9C61.0Z Approved [4]
Dichlorphenamide Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Carbonic anhydrase I (CA-I) TTHQPL7 CAH1_HUMAN Modulator [9]
Carbonic anhydrase II (CA-II) TTANPDJ CAH2_HUMAN Inhibitor [10]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7248).
3 Nizatidine FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6807).
5 Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7.
6 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00585)
7 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
8 Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide. J Pharm Pharmacol. 2002 Nov;54(11):1559-63. doi: 10.1211/002235702117.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.